
Learn how total, free and bound testosterone differ, why SHBG matters, and how clinical guidance puts blood test results in context.

Total testosterone is the combined amount of protein-bound and unbound testosterone measured in blood. Free testosterone is the unbound portion. Bound testosterone is attached to blood proteins such as sex hormone-binding globulin (SHBG) and albumin, which hold the hormone with different strengths.
A total testosterone test therefore measures an overall concentration rather than giving a separate reading for each fraction. The NCBI Bookshelf review Androgen Physiology, Pharmacology, Use, and Misuse explains these forms of circulation and the differences between their binding proteins.
SHBG binds testosterone more tightly than albumin and other lower-affinity blood proteins. This binding is part of what a total testosterone result includes. Total testosterone does not exclude hormone simply because it is attached to SHBG.
Albumin-bound testosterone is often grouped with free testosterone under the term bioavailable testosterone. The reason is that albumin binds less tightly than SHBG, according to the physiology review. Bioavailable testosterone is therefore not another name for free testosterone alone.
The proportions can depend on how the fractions are defined. A fixed albumin-bound percentage should not be assumed to apply universally. Keeping these labels distinct helps when comparing the forms measured or estimated in bloodwork.
Free testosterone describes a binding state, not a separate hormone. A total result includes this fraction but does not tell the reader how much is free. That distinction becomes important when a clinician is trying to understand an unexpected relationship between total and free results.
The physiology review cautions that the biological significance of dividing testosterone into these fractions remains debated. It also discusses possible roles for SHBG in cellular uptake and signaling. The free fraction should not be described as the only biologically active form, and the bound fraction should not be treated as inert. These labels describe circulation more simply than they describe all testosterone action.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret symptoms and laboratory results and make any diagnosis or treatment decisions.
The European Association of Urology (EAU) identifies 12 nmol/L (3.5 ng/mL) as a reliable total-testosterone threshold in its guidance on late-onset hypogonadism. That threshold is interpreted alongside compatible symptoms and repeat measurements. It is not a complete lower-to-upper laboratory reference interval or a personal treatment target.
Biologically, this number concerns the combined concentration of free and protein-bound testosterone. It does not specify the distribution between those fractions. The same total result need not imply the same free result in every man because SHBG can affect that relationship.
The EAU recommends assessing low morning total testosterone on at least two occasions using a reliable assay and fasting samples. It specifies morning testing between 07:00 and 10:00 and repeating a low result before treatment.
Those conditions are part of confirming a low finding, not instructions to begin treatment if a number crosses the threshold. Understanding why blood-draw conditions matter gives the repeat result a clearer role in the medical conversation.
The EAU identifies equilibrium dialysis as the most accurate method for measuring free testosterone. It also describes calculation using total testosterone with SHBG and albumin. A reported free value may therefore be a measurement or an estimate, and the laboratory method matters.
The NCBI-hosted review notes limitations in measurement and calculation methods. It also notes the lack of a universal validated free-testosterone reference range in some settings and describes the clinical utility of derived free or bioavailable measures as controversial. A calculated result should therefore not be treated as interchangeable with every other free-testosterone result.
The useful clinical question is which method and interpretive range apply to the report in front of the clinician. Neither a total-testosterone threshold nor a free-testosterone estimate supplies the entire assessment.
For an adult man, an out-of-range result raises an assessment question rather than naming a symptom syndrome. The EAU framework requires symptoms compatible with low testosterone alongside the biochemical evidence described above. A low result does not establish what a man is experiencing, and a symptom by itself does not establish a hormone diagnosis.
When describing a concern to a clinician, the useful distinction is between the experience and the explanation. What has changed and how it affects everyday life are matters for the clinical history. Whether testosterone is involved is a separate question that requires the laboratory context.
Higher or lower SHBG is likewise not a symptom diagnosis. Its role in this discussion is to help explain the relationship between hormone measurements, not to supply a separate label for how a man feels. The free and bound fractions should not be assigned separate symptom lists from the blood results alone.
The physiology review lists several factors associated with higher or lower SHBG. These associations help explain why a binding-protein result can matter when total and free testosterone appear inconsistent. They are not proof that any one factor explains an individual's results.
These are associations with SHBG, not a list of fixed changes in free testosterone. Reading them as a direct prediction of the free result would skip the relationship between total hormone and binding proteins. Their value is in providing context for a clinician's interpretation.
The EAU strongly recommends measuring SHBG and calculating free testosterone in conditions characterized by altered SHBG. This supports targeted assessment when binding may be affecting the picture. It does not make total testosterone meaningless or require every man to receive every available hormone test.
Obesity is one example where body-fat context belongs in hormone interpretation. The review associates it with lower SHBG, rather than establishing that body size alone identifies a testosterone disorder.
Medication history also matters because the review lists estrogens and anticonvulsants among higher-SHBG associations and androgens among lower-SHBG associations. Reviewing that history with a clinician is different from changing a medicine to alter a laboratory value.
A higher SHBG result is not automatically proof of low free testosterone. A lower result does not automatically establish the opposite. The EAU approach is to assess the relevant measures together when SHBG may be altered, rather than infer an unbound concentration from the protein result alone.
Ask your physician: “Do my symptoms and repeat fasting morning tests support low testosterone?” “Could my health conditions or medicines affect SHBG?” “Was my free testosterone measured or calculated and what limits apply to that method?”
Blood-protein binding makes a single testosterone number an incomplete description of hormone distribution, so Testostra explains these results within their clinical limits. Its evidence-led coverage connects total testosterone with free testosterone and SHBG so readers have clearer terms for discussing their laboratory reports, rather than a self-directed hormone plan.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra